SUMMARY A 44-year-old woman is described with an endocrine tumour arising in the kidney. There were associated abnormalities of small intestinal morphology, motility, and absorptive function. These abnormalities reversed on removal of the tumour. Detailed studies showed that the tumour contained, and was secreting, glucagon. It is postulated that the intestinal abnormalities may have resulted from glucagon itself or another, as yet unidentified, hormone.
Histochemistry
The methods used were essentially the same as previously described (Rost, Polak, and Pearse, 1969) . Two blocks of tissue were quenched in Arcton 22 (Freon 22) , one for freeze drying followed by exposure to formaldehyde vapour to investigate fluorogenic amine content (Table I) , the other for cryostat sections to stain for enzymes which are usually present in endocrine polypeptide producing cells.
Another feature of cells of the endocrine polypeptide series (called APUD cells by Pearse (1969) from the initial letters oftheir staining characteristics) ( Table I) is their uptake of amine precursors (5-HTP and DOPA) which was tested in vitro (Table I) . To confirm the presence of secretory granules, tumour blocks were fixed in 6% gluteraldehyde in 0.1 M phosphate buffer saline, at pH 7.4, and 5 g sections stained (Table I ). In addition, since tryptophan is found in some endocrine polypeptide hormones, including glucagon, this amino acid was investigated with Lillie's xanthydrol method (Solcia, Sampietro, and Capella, 1969) .
Immunofluorescence
The tumour was also examined for polypeptide hormone production by an indirect immunofluorescence technique (Coons, Leduc, and Connolly, 1955) using specific antisera (Table I) . Details of tissue processing, the controls used, and the technique for globulin extraction from antisera were the same as those previously used to demonstrate polypeptide hormones in different gastrointestinal tissues (Polak, Coulling, Doe, and Pearse, 1971; Polak, Bloom, Coulling, and Pearse, 1971) .
ANTISERA
The globulin fractions of the antisera which were used in the immunofluoroscence studies were prepared as follows: 
Glucagon
The same glucagon antiserum (prepared by one of us-S.R.B.) was used both for immunofluorescence and for radioimmunoassay. There was no cross reaction between this antiserum and rabbit antisynthetic procine secretin (Polak, 1971) .
For controls the above antisera were absorbed with an excess of the appropriate antigen.
RADIOIMMUNOASSAY AND BIOASSAY
The glucagon activity of both tumour and preoperative plasma was measured by radioimmunoassay (Albano and Elkins, 1970) using a rabbit antiporcine pancreatic glucagon antiserum (BlO) and crystalline porcine pancreatic glucagon standards (Novo batch B69). Incubation damage was minimized by the addition of aprotinin (F.B.A. Pharmaceuticals) and antibody-bound and free hormone separated with dextran-coated charcoal.
The glucagon activity in a 20% (w/v) saline homogenate of the tumour was also assayed biologically using 200 g Porton rats. After a two-hour control period, during which baseline blood samples were obtained from a carotid artery cannula, 0.1 ml of tumour extract was injected into the external jugular vein of the rats and further arterial blood samples were taken three, six, 10, and 20 minutes later. Plasma glucose was estimated using glucose oxidase (Technicon AutoAnalyzer) and plasma immunoreactive insulin was assayed using Wellcome MR58 antiserum and rat insulin standard (Novo R169).
Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function There was no proteinuria (24-hour urine protein nil on two occasions). Urine microscopy showed no red blood cells but occasional pus cells were found and, on culture, the urine grew occasional E. coli. The endogenous creatinine clearance was 143 ml/min.
INTESTINAL FUNCTION
Mild steatorrhoea had been found at Essex County Hospital (faecal fat 8 g/24 hours), which was confirmed at Hammersmith Hospital (faecal fat 20 g/ 24 hr).
Urinary xylose excretion was normal-10X8 g/5 hours. The glucose tolerance test, rather than indicating malabsorption, showed a mildly diabetic pattern, the fasting blood sugar of 70 mg/100 ml rising to 215 mg at one hour and falling to 120 mg at two hours and 82 mg/100 ml at two-and-a-half hours.
There was no evidence of protein-losing enteropathy, only 1.4% of a dose of intravenous 51CrCl being excreted over a four-day period. Urinary indican excretion, however, was markedly raised-560 mg/24 hours.
The Schilling test showed vitamin B,2 malabsorption both without (1-5 % excreted/24 hours) and with (1-7°) intrinsic factor.
INTESTINAL STRUCTURE
A barium enema showed obvious faecal retention but the colon was otherwise normal. However, on barium follow-through the small intestine was grossly abnormal (Fig. la) , being dilated with coarse, thickened mucosal folds. Intestinal transit was slow, the barium taking 14 hours to reach the colon. There was also a marked increase in calibre of the intestine, with an average diameter of jejunum of approximately 50 mm, the upper limit of normal being less than 30 mm (Laws, Booth, Shawdon, and Stewart, 1963) .
Progress and Treatment
The persistence of structural and functional small bowel changes led to a laparotomy on 22 January 1970.
LAPAROTOMY FINDINGS (MR MANTOUDIS)
The pelvic organs, liver, and spleen were normal and by that time there was no ascites. The main abnormality was marked hypertrophy and oedema of the small bowel wall which was present along the whole length of the small intestine but was more obvious in jejunum than in ileum. A full-thickness biopsy was taken from mid-jejunum. Again, there was gross retention of faeces in the colon. shows normal diameter and normal mucosal pattern. Fig. 1 Small bowel follow-through. The most remarkable feature was hypertrophy of the villi, which were easily visible to the naked eye-an appearance confirmed on dissecting microscopy ( Fig. 2) . In well orientated histological sections runs of villi measured (with a micrometer eyepiece) on average 1,150 g with occasional villi (Fig. 3) (Figs. 2 and 3 ).
The abdomen was explored and no other tumour was palpated; in particular, the pancreas appeared normal.
Nephrectomy Specimen MACROSCOPIC FEATURES
The cut surface of the right kidney showed a soft, round, yellowish tumour, demarcated from surrounding renal parenchyma by awell definedcapsule. There was no haemorrhage or necrosis in the tumour and calcium was present in its periphery, suggesting that it was a slow growing lesion.
LIGHT MICROSCOPY
The histology of the tumour was not that of a renal carcinoma but strongly suggested an endocrine tumour.
The histological pattern varied from one part of the tumour to the next. In some areas there were islands of small ovoid cells surrounded by a palisade layer of tall cuboidal cells (Fig. 4a ) while in other areas there were interlacing and winding ribbons of columnar cells (Fig. 4b) . In general, the tumour cells were well differentiated with few mitotic figures. The cells were weakly argyrophil but did not display argentaffinity. The stroma varied in amount and contained numerous capillaries. In places where the renal capsule was invaded the tumour also involved the vascular channels.
ELECTRON MICROSCOPY
The tumour was composed of light and dark epithelial cells with a basement membrane present where the cells bordered on connective tissue. The nuclei were large, central, and vesicular with marginated chromatin and large prominent nucleoli and the Golgi complex was well developed (Fig. 5) .
The most striking feature, however, was the presence of distinctive spherical electron-dense secretory granules measuring 100-200 m,u in diam- eter (Fig. 5 inset) . These were most numerous in the palisade layer of cells and showed a polar arrangement in that they tended to be aggregated at the vascular pole of the cells.
HISTOCHEMISTRY
The results of the cytochemical studies are given in Table I . The patient's tumour cells fulfilled the classical cytochemical criteria for polypeptide hormone-secreting or APUD cells (Table I ). The storage granules in the tumour tissue also stained strongly for tryptophan, suggesting either a carcinoid or pancreatic islet a2 cell tumour.
A strongly positive reaction was seen with antiglucagon on tissue sections (Fig. 6) . Antisera against gastrin, calcitonin, growth hormone, and ACTH gave no fluorescence. A weak positive reaction was obtained with anti-insulin; this was probably due to impurity, since it is difficult to obtain anti-insulin without some anti-glucagon activity.
RADIOIMMUNOASSAY AND BIOASSAY
The patient's fasting preoperative plasma immunoreactive glucagon was more than 10 times normal at 6 ng/ml (the normal immunoreactive glucagon equivalent in the fasting subject is 0A45 ng/ml). The Fig. 6 Immunofluorescence demonstration ofglucagon in the renal tumour, showing localization offluorescence similar to that ofsecretory granules as shown by electron microscopy ( x 400). glucagon content of the tumour, also measured by radioimmunoassay, was 0.15 mg/g wet weight tissue.
The injected dose of saline tumour extract, which contained 3 ,ug immunoreactive glucagon, produced a marked rise in plasma insulin from the baseline level of 25 ,uU to 110 ,uU/ml in three minutes. After 10 minutes the injection also produced a sustained rise in plasma glucose from a constant baseline value of 140 mg/100 ml to 260 mg/100 ml, and there was a further rise to 310 mg/100 ml over the next 20 minutes.
Progress after Nephrectomy
After removal of the tumour there was a marked change in the clinical picture. The patient's constipation disappeared almost immediately; in fact, on the second postoperative day she had 12 bowel motions and subsequently she has had a tendency to loose and frequent stools (three to four a day). Hair growth has returned to normal and menstruation has begun again. There was an obvious improvement in the radiological appearances of the intestine, the diameter of the small bowel and the mucosal pattern returning to normal (Fig. lb) . In contrast to the slow intestinal transit before nephrectomy, the barium now traversed the small bowel very rapidly, reaching the colon in 20 minutes. A peroral jejunal biopsy showed that the mucosa had also become normal, with normal villous height and no longer any suggestion of oedema in the lamina propria or epithelial cells. Vitamin B12 absorption, both with and without intrinsic factor, was normal (15-2%) and the urinary indican excretion had also fallen to normal levels (40 mg/24 hours). Faecal fats, however, have varied from normal levels to values of 12 g/24 hours. The glucose tolerance test no longer showed a diabetic pattern and was entirely normal.
Discussion
Glucagon-secreting tumours are extremely rare, and in the few previously reported glucagonomas there have been no consistent clinical features. However, some of the findings in the present patient have been noted previously.
Hyperinsulinism secondary to excess circulating glucagon may present, as in this case, with abnormal glucose tolerance (Unger et al, 1964) or with frank diabetes (McGavran et al, 1966) . Mild abnormalities of liver-function have been described before by Yoshinaga et al (1966) whose patient with a pancreatic A cell tumour also had secondary amenorrhoea though the mechanism for these clinical features is unknown. Several other unexplained aspects in the present case have also been previously described in glucagonomas, namely, a skin rash, haemolytic anaemia, and oedema. McGavran et al (1966) described a bullous eczematoid dermatitis affecting hands, feet, and legs, and their patient was also noted to have oedema. These authors also described anaemia with increased reticulocytes and a negative Coombs test associated with a glucagon-secreting a-cell carcinoma of the pancreas.
The changes in small bowel structure, motility, and absorptive function noted in our patient have not been previously described in association with glucagonoma. In fact, McGavran et al (1966) specifically mentioned that barium studies in their patient showed a normal small bowel. The question arises, therefore, can glucagon (either on its own or possibly in association with other hormones secreted by the tumour) produce the intestinal changes described in this patient? It is known that glucagon increases mesenteric blood flow in dogs (Kock, Tibblin, and Schenk, 1970) but whether increased blood flow stimulates small bowel hypertrophy is clearly unknown. It is, of course, possible that, in addition to glucagon, the tumour was elaborating a second hormone which directly stimulated villous growth. The precedent that a tumour might produce two hormones has been established by Unger et al (1964) who described the production both of insulin and glucagon in metastases from a bronchogenic carcinoma. Furthermore, the concept of an 'intestinal epithelial growth hormone' is not new and was postulated by Loran and Crocker (1963) to explain increased cell turnover (Loran and Althausen, 1960) and intestinal hypertrophy which are seen in the residual small bowel of rats following intestinal resection (Booth, Evans, Menzies, and Street, 1959; Dowling and Booth, 1967) . Loran and Carbone (1968) showed by cross-circulation experiments that there was an increased rate of cell turnover in the small intestine of the unoperated rat after resection of the small bowel in its parabiotic mate. However, the experimental data are far from conclusive and there is no direct evidence that such a hormone exists in man.
The constipation which was such a prominent feature in the present patient's symptoms may have been due to glucagon since it is known that glucagon inhibits motility in the human jejunum and colon (Kock, Darle, and Dotevall, 1967) . Whether the disturbance in intestinal motility caused by glucagon could produce a blind loop syndrome is open to question. The pattern of absorptive defect seen here with steatorrhoea, vitamin B12 malabsorption, and gross indicanuria is compatible with a stagnant loop picture. Whether hypomotility alone without an associated anatomical defect producing stasis can cause a blind loop syndrome in man remains to be proven, although Hershenson (1965) induced fat malabsorption in the human subject by reducing intestinal motility with probanthine. The definitive proof of a blind loop syndrome by aspiration of intestinal juice for quantitative bacteriological and bile salt studies was not possible before surgery in our patient because of difficulties with duodenal intubation.
Another possible explanation for the patient's malabsorption of fat and vitamin B12 is exocrine pancreatic insufficiency since it is known that glucagon may inhibit pancreatic exocrine secretion (Dyck, Texter, Lasater, and Hightower, 1970) . Although no direct assessment of pancreatic exocrine function was made, pancreatic insufficiency is a less likely explanation for the patient's malabsorption since low rather than high levels of urinary indican excretion would be expected in this situation (Neale, Lambert, and Gorbach, 1969) .
The evidence presented in this paper suggests that the tumour was indeed producing glucagon. Light and electron microscopy suggested that the tumour was endocrine in type and the size of the secretory granules seen on electron microscopy were similar to those described in pancreatic A cells. The histochemical findings suggested that the tumour was producing glucagon, either alone or in combination with another polypeptide hormone (or at least, that it was secreting a polypeptide which cross-reacted with anti-glucagon serum). The specificity of both the immunofluorescent studies and the radioimmunoassay depends, of course, on the antiserum used, and in the present studies pancreatic glucagon antiserum was used. It might be argued that if the tumour in the present case were secreting enteroglucagon rather than pancreatic glucagon the antiserum might not cross-react. However, this objection is largely negated by the disappearance of immunofluorescence when the antiserum was absorbed with an excess of the antigen. Furthermore, the bioassay (which is clearly not dependent on antigenic fractions of the molecule) provides convincing proof that the polypeptide secretion was indeed glucagon.
The effects of injecting experimental animals with extracts of tumour and of the patient's preoperative serum on small bowel structure and function are now being studied. In addition, the chemical nature of the polypeptide hormone is being analysed, and the results of these studies will be the subject of further communications. 
